Bank Of New York Mellon Corp Taysha Gene Therapies, Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.76 - $4.94 $660 - $1,852	-375 Reduced 3.21%	11,295 $22,000
Q2 2022 Aug 15, 2022	SELL	$2.47 - $6.77 $164,420 - $450,658	-66,567 Reduced 85.08%	11,670 $44,000
Q1 2022 May 11, 2022	BUY	$5.22 - $11.86 $10,789 - $24,514	2,067 Added 2.71%	78,237 $510,000
Q4 2021 Feb 11, 2022	BUY	$11.43 - $19.2 $27,717 - $46,560	2,425 Added 3.29%	76,170 $887,000
Q3 2021 Nov 12, 2021	BUY	$15.82 - $21.57 $270,094 - $368,264	17,073 Added 30.13%	73,745 $1.37 Million
Q2 2021 Aug 11, 2021	BUY	$19.29 - $26.38 $573,684 - $784,541	29,740 Added 110.43%	56,672 $1.2 Million
Q1 2021 May 13, 2021	SELL	$20.3 - $31.75 $974 - $1,524	-48 Reduced 0.18%	26,932 $546,000
Q4 2020 Feb 09, 2021	BUY	$19.14 - $28.13 $516,397 - $758,947	26,980 New	26,980 $716,000

118

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $73M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.